Mangalam Drugs & Organics Ltd
Company Profile
Business description
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
Contact
P. D'Mello Road
Rupam Building, 3rd Floor, No. 239
Near General Post Office
MumbaiMH400001
INDT: +91 2222616200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
480
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
stocks
Undervalued ASX retailer benefiting from rebound in spending
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,923.80 | 7.50 | -0.08% |
| CAC 40 | 8,152.12 | 83.50 | 1.03% |
| DAX 40 | 24,281.60 | 95.11 | 0.39% |
| Dow JONES (US) | 48,458.05 | 245.96 | -0.51% |
| FTSE 100 | 9,740.77 | 91.74 | 0.95% |
| HKSE | 25,628.88 | 347.91 | -1.34% |
| NASDAQ | 23,195.17 | 398.69 | -1.69% |
| Nikkei 225 | 50,168.11 | 668.44 | -1.31% |
| NZX 50 Index | 13,408.14 | 1.23 | 0.01% |
| S&P 500 | 6,827.41 | 73.59 | -1.07% |
| S&P/ASX 200 | 8,635.00 | 8.90 | -0.10% |
| SSE Composite Index | 3,867.92 | 21.42 | -0.55% |